Surrozen, Inc (SRZN) News
Filter SRZN News Items
SRZN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SRZN News From Around the Web
Below are the latest news stories about SURROZEN INC that investors may wish to consider to help them evaluate SRZN as an investment opportunity.
Surrozen to Present at Upcoming Healthcare Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, President and Chief Executive Officer, will present at two upcoming healthcare investor conferences. Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024 Fireside Chat at 3:00 PM ET / 1 |
Surrozen Provides Third Quarter 2024 Financial Results and Business UpdateSubstantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of preclinical ophthalmology product candidates to R&D pipeline Received $10 million milestone payment from Boehringer Ingelheim strategic collaboration on SZN-413 in retinal vascular associated diseases SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “C |
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FibrosisResearch collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary FibrosisSOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a strategic research collaboration with privately-he |
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases CollaborationBoehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wingless/Integrated (Wnt) signaling, designed using Surrozen’s SWAP™ technology SZN-413 offers the possibility of restoring retinal function in patients living with retinal vascular diseases SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SR |
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite RiskyWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Surrozen Provides Second Quarter 2024 Financial Results and Business UpdateEnrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis Presented first-in-human data from SZN-043 Phase 1a trial at EASL Published study that demonstrated application of unique Targeted Protein Degradation technologies resulting in robust Wnt signal activation in bispecific antibodies based on the Company's SWEETS technology platform SOUTH SAN FRANCISCO, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a comp |
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt SignalingTargeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies Results demonstrated that the two new ASGR-targeted SWEETS bispecific antibodies enhanced Wnt-signal activation through the unique TPD platform SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulat |
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in MilanSZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Phase 1a trial of SZN-043 demonstrated evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver Enrollment is ongoing in Phase 1b study in severe alcohol-associated hepatitis SOUTH SAN FRANCISC |
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated HepatitisSZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical |
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual MeetingIn preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the corneaSurrozen’s antibody based Wnt mimetic also increased detectable tear volume production in dry eye disease models SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for |